GVR Report cover U.S. Home Infusion Therapy Market Size, Share & Trends Report

U.S. Home Infusion Therapy Market Size, Share & Trends Analysis By Product (Infusion Pumps, Needleless Connectors), By Application (Anti-Infective, Endocrinology), And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-3-68038-956-2
  • Number of Pages: 116
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The U.S. home infusion therapy market size was estimated at USD 16.6 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.5% from 2022 to 2030. The growing elderly population prone to various severe disorders is one of the major drivers for the market growth. The growing geriatric population and increasing prevalence of cancer, Crohn's disease, multiple sclerosis, nutritional and immune deficiencies, infections, dehydration, and nausea & vomiting are majorly driving the growth. The COVID-19 outbreak increased the importance and demand for medical devices especially in a home-based setting as the virus is transmitted through physical contact. The market witnessed revenue growth in 2020, but the key players faced supply chain bottlenecks. However, in 2021, key players like Baxter, Option Healthcare, and Smiths Medical reported a soaring revenue increase as compared to 2020, especially in the U.S.

U.S. home infusion therapy market size, by product, 2020 - 2030 (USD Billion)

For instance, Baxter reported an eight percent increase in sales revenue in the third quarter of 2021 compared to 2020. Growth of 14.1% ($891.9 million) was reported by Option Care Health Inc. in the third quarter of 2021 compared to $781.6 million in 2020. This indicates that the market is recovering at a conspicuous rate and is expected to boost further.

Home infusion therapy offers various benefits. They are convenient, cost-effective, offer better outcomes, and have higher safety standards. Compared to hospital treatment, home infusion therapy is cost-effective since eliminates hospital stays that ultimately saves the patients money. It also allows the patient to maintain higher safety due to less risk of hospital-acquired infections at home.

Increasing patients’ preference for home therapy is also driving the growth of the U.S. home infusion therapy market. Home healthcare supports the daily life activities of patients and has better access to skilled medical care with advanced healthcare services. In addition, geriatric patients with chronic disorders and individuals recently discharged from hospitals and other healthcare settings are expected to be at high nutrition risk and can get home-cooked meals. These factors are expected to drive market growth over the forecast period.

Growing advancements in-home healthcare industry is also expected to fuel the market expansion in the forthcoming years. Availability of Point-of-Care (POC) diagnostics that help in faster patient care and provision of telehealth programs for patients suffering from chronic disorders and who need to be admitted frequently is trending. The pandemic has had a positive impact on the market in 2021. According to McKinsey, emergency room visits in the U.S. were down by half or more and faced an accelerated decline throughout the year. This led healthcare practitioners to prescribe patients home infusion treatments to monitor them remotely which is safe for the patient and also reduces the burden on a healthcare facility.

Product Insights

Among other segments, infusion pumps held a larger share of 50.8% of the market in 2021. This can be attributed to their increasing use and efficiency in delivering nutrition, medications, and other required fluids in required amounts. In addition, modernized infusion pumps are equipped with alert systems to avoid the risk of adverse drug interaction or when the pump parameters are indifferently set. These factors are expected to drive the segment growth in the forthcoming years.

Needleless connectors is expected to be the fastest-growing segment over the forecast period owing to various benefits, such as less risk of bacterial contamination and higher protection against needlestick injuries. Moreover, needleless connectors reduce the risk of Healthcare Associated Bloodstream Infections (HA-BSIs). Owing to these features, the demand for needleless connectors is predicted to augment over the forecast period.

Application Insights

The anti-infective segment registered a significant share of 27.2% in 2021. By application, the market is divided into anti-infective, endocrinology, hydration therapy, parenteral nutrition, enteral nutrition, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment registered a significant revenue share in 2021, owing to its extensive use as antifungal, antibiotics, and antiviral agents in at-home care. Moreover, growing efforts for reducing hospital stays are also increasing the demand for anti-infective therapy, thereby driving the market growth.

U.S. home infusion therapy market share, by application, 2021 (%)

Endocrinology is predicted to be the fastest-growing segment in the forthcoming years, owing to the growing number of conditions associated with the endocrine system. Thyroid is one of the most common disorders prevalent in the U.S, sometimes resulting in death. According to the American Cancer Society, 2019, approximately 52,070 thyroid cancer cases have been registered (14,260 in males and 37,810 in females). Hence, growing cases of thyroid along with metabolic disorders in the U.S. are expected to drive the growth of the segment.

Regional Insights

Owing to increasing chronic disorders prevalent in individuals and growing initiatives by the government for the advantages of home infusion therapy, the U.S. market for home infusion therapy is expected to grow considerably. Moreover, increasing demand for long-term therapies by patients is also expected to fuel market growth in the future.

Major factors driving market growth include an increase in the geriatric population and a rise in disease burden. In addition, growing awareness has led to a higher inclination of patients, especially the geriatric population, requiring long-term care toward home infusion therapy. It has been estimated that administration of medications at home costs from USD 150 to USD 200 per day, much lesser than the cost of a typical inpatient stay, which costs from USD 1,500 to USD 2,500 per day.

The well-established healthcare industry, easy access to healthcare needs, faster adoption of advanced technologies, and high disposable income of consumers are a few other drivers of the market growth. The availability of superior quality home infusion products to the patients is also propelling the growth of the market.

Key Companies & Market Share Insights

The players operating in the market for home infusion therapy in the U.S. are focusing on adopting growth strategies, such as mergers and acquisitions, new product launches, innovations in the existing technologies, and more.

Recent Developments:

  • In December 2021, Baxter International completed the acquisition of Hillstrom. This acquisition will help the company in broadening its geographic footprint and integrating medical device technology that will enhance patient care, lower costs and increase workflow efficiency

  • In May 2021, Smiths Medical and Ivenix, Inc. announced a partnership agreement to offer a comprehensive suite of infusion management solutions in the U.S. market. This partnership is expected to evolve infusion management to improve patient safety

  • In April 2020, Option Care Health announced an expansion of its partnership with Regence Health (a committee that helps ease the burden on hospitals in the U.S) to increase access to healthcare at home for high-risk patients that rely on infusion services

Some prominent players in the U.S. home infusion therapy market include:

  • B. Braun Melsungen

  • Baxter International

  • Caesarea Medical Electronics Ltd.

  • CareFusion

  • Fresenius Kabi

  • ICU Medical

  • JMS CO., LTD.

  • Smiths Medical, Inc.

  • Terumo Corporation

  • Coram LLC

  • Option Care Enterprises, Inc.

  • BioScrip, Inc.

  • BriovaRx Infusion Services

  • Paragon Healthcare

U.S. Home Infusion Therapy Market Report Scope

Report Attribute


Market size value in 2022

USD 17.9 billion

Revenue forecast in 2030

USD 31.7 billion

Growth Rate

CAGR of 7.5% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2019 to 2026

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Product, application, route of administration

Country scope


Key companies profiled

B. Braun Melsungen; Baxter International; Caesarea Medical Electronics Ltd.; CareFusion; Fresenius Kabi; ICU Medical; JMS CO., LTD.; Smiths Medical, Inc.; Terumo Corporation; Coram LLC; Option Care Enterprises, Inc.; BioScrip, Inc.; BriovaRx Infusion Services; Paragon Healthcare

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the U.S. home infusion therapy market report based on product, application, route of administration and region:

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Infusion Pumps

    • Intravenous Sets

    • IV Cannulas

    • Needleless Connectors

  • Application Outlook (Revenue, USD Million, 2017 - 2030)

    • Anti-infective

    • Endocrinology

      • Diabetes

      • Others

    • Hydration Therapy

      • Athletes

      • Others

    • Chemotherapy

    • Enteral Nutrition

    • Parenteral Nutrition

    • Specialty Pharmaceuticals

    • Others

  • Route of Administration Outlook (Revenue, USD Million, 2017 - 2030)

    • Intravenously

    • Subcutaneously

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.